These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32868353)

  • 1. Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.
    Huang X; Weng X; Lin S; Liu Y; Luo S; Wang H; Ming WK; Huang P
    BMJ Open; 2020 Aug; 10(8):e036107. PubMed ID: 32868353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.
    Liao W; Huang J; Wu Q; Wen F; Zhang N; Zhou K; Bai L; Li Q
    Breast Cancer; 2020 May; 27(3):399-404. PubMed ID: 31853795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
    Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
    Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer.
    Ding H; Fang L; Xin W; Tong Y; Zhou Q; Huang P
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28675545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis.
    Huang X; Lin S; Rao X; Zeng D; Wang H; Weng X; Huang P
    Clin Breast Cancer; 2021 Aug; 21(4):e479-e488. PubMed ID: 33676870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
    Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
    Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
    Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
    Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model.
    Lux MP; Hartmann M; Jackisch C; Raab G; Schneeweiss A; Possinger K; Oyee J; Harbeck N
    Breast Cancer Res Treat; 2009 Sep; 117(2):305-17. PubMed ID: 19130218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic evaluation of fulvestrant 500 mg versus generic nonsteroidal aromatase inhibitors in patients with advanced breast cancer in the United Kingdom.
    Das R; Cope S; Ouwens M; Turner P; Howlett M
    Clin Ther; 2013 Mar; 35(3):246-260.e5. PubMed ID: 23453402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).
    Kim JY; Im SA; Jung KH; Ro J; Sohn J; Kim JH; Park YH; Kim TY; Kim SB; Lee KS; Kim GM; Kim SH; Kim S; Ahn JS; Lee KH; Ahn JH; Park IH; Im YH;
    Eur J Cancer; 2018 Nov; 103():127-136. PubMed ID: 30223226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?
    Darvishi A; Abdi Dezfouli R; Fazaeli A; Daroudi R; Zandieh N
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1201-1210. PubMed ID: 37768209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
    Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
    Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.
    Ward MC; Vicini F; Chadha M; Pierce L; Recht A; Hayman J; Thaker NG; Khan A; Keisch M; Shah C
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):296-306. PubMed ID: 31212043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
    Stellato D; Thabane ME; Park J; Chandiwana D; Delea TE
    Pharmacoeconomics; 2021 Sep; 39(9):1045-1058. PubMed ID: 34105083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fulvestrant for hormone-sensitive metastatic breast cancer.
    Lee CI; Goodwin A; Wilcken N
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011093. PubMed ID: 28043088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?
    Wu W; Lin H; Cai J; Sun H; Liu J; Hu C; Wei X
    Clin Drug Investig; 2023 Dec; 43(12):939-948. PubMed ID: 37975961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2- Advanced or Metastatic Breast Cancer: A US Payer Perspective.
    Wang Y; Rui M; Guan X; Cao Y; Chen P
    Front Med (Lausanne); 2021; 8():658747. PubMed ID: 34150798
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.